文献速递白内障与屈光手术眼底病与葡萄膜炎

多中心葡萄膜炎类固醇治疗(MUST)试验及随访研究中接受全身治疗的葡萄膜炎患者白内障手术的风险因素与结局

Cataract Surgery in Patients With Uveitis Treated With Systemic Therapy in the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study: Risk Factors and Outcomes.
PubMed 文献 · Am J Ophthalmol · 2023-07-03

基于MUST试验及随访研究中接受全身皮质类固醇和免疫抑制治疗的中间型、后型和全葡萄膜炎患者队列,125只晶状体眼7年白内障手术累积发生率为43%且风险未趋于平稳;年龄>50岁、局部皮质类固醇使用、青光眼药物使用为风险因素,白内障术后1年视力结局总体良好。

要点

  • 接受全身治疗的中间型、后型和全葡萄膜炎患者7年白内障手术累积发生率为43%,风险未趋于平稳。
  • 白内障手术风险因素包括年龄>50岁(HR 2.86)、局部皮质类固醇使用(时变HR 3.13)、青光眼药物使用(HR 2.75)。
  • 42只眼白内障术后1年视力中位增益4.8行,中位最佳矫正视力20/25。

核心结论

  • 在接受口服皮质类固醇和免疫抑制治疗的中间型、后型和全葡萄膜炎患者中,长期白内障手术风险较高,但白内障手术后视力结局总体良好。

研究设计与样本

  • 研究设计为随机临床试验的队列研究,研究对象来自多中心MUST试验及随访研究中分配至全身治疗的参与者。
  • 纳入74例中间型、后型或全葡萄膜炎患者的125只晶状体眼,均接受全身治疗。
  • 主要结局指标为白内障手术发生率及白内障手术后视力。

主要发现

  • 7年随访时白内障手术累积发生率为43%,且风险未趋于平稳。
  • 白内障手术风险因素包括年龄>50岁(HR 2.86,95%CI 1.52-5.42;P=.001)、局部皮质类固醇使用(时变HR 3.13,95%CI 1.42-6.94;P=.005)、青光眼药物使用(HR 2.75,95%CI 1.38-5.47;P=.004),以及可能的前房炎症病史(HR 1.90,95%CI 0.95-3.84;P=.07)。
  • 在42只接受白内障手术且有1年随访数据的眼中,术后1年视力中位增益为4.8行,中位最佳矫正视力为20/25。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the rate of, risk factors for, and outcomes of cataract surgery in patients with intermediate, posterior, and panuveitides treated with systemic corticosteroids and immunosuppression. DESIGN: Cohort study of participants from a randomized clinical trial. METHODS: A multicenter clinical trial with extended follow-up comprised the study setting. From the cohort of participants assigned to systemic therapy in the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study, 125 phakic eyes of 74 patients with intermediate, posterior, or panuveitides treated with systemic therapy were included. The main outcome measures were cataract surgery and visual acuity after cataract surgery. RESULTS: The cumulative incidence of cataract surgery was 43% at 7 years of follow-up, and the risk did not plateau. Risk factors for cataract surgery included age >50 years (hazard ratio [HR] 2.86, 95% CI 1.52, 5.42; P = .001), topical corticosteroid use (time-updated HR 3.13, 95% CI 1.42, 6.94; P = .005), glaucoma medication use (HR 2.75, 95% CI 1.38, 5.47; P = .004), and possibly history of anterior chamber inflammation (HR 1.90, 95% CI 0.95, 3.84; P = .07). Median gain in acuity and median best corrected visual acuity 1 year after cataract surgery were 4.8 lines and 20/25, respectively, among 42 eyes undergoing cataract surgery with 1-year follow-up data. CONCLUSIONS: Among patients with intermediate, posterior, and panuveitides, treated with oral corticosteroids and immunosuppression, there is a substantial long-term risk of cataract surgery. Visual acuity outcomes after cataract surgery are generally good.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Jabs DA, Sugar EA, Burke AE, et al. Cataract Surgery in Patients With Uveitis Treated With Systemic Therapy in the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study: Risk Factors and Outcomes. Am J Ophthalmol. 2023. PMID: 37406846. doi:10.1016/j.ajo.2023.06.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。